{"id":"https://openalex.org/W2402377796","doi":null,"title":"Relative bioavailability of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in rats and monkeys.","display_name":"Relative bioavailability of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in rats and monkeys.","publication_year":1996,"publication_date":"1996-01-01","ids":{"openalex":"https://openalex.org/W2402377796","mag":"2402377796","pmid":"https://pubmed.ncbi.nlm.nih.gov/9414389"},"language":"en","primary_location":{"id":"pmid:9414389","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9414389","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of experimental therapeutics & oncology","raw_type":"Comparative Study"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5012634145","display_name":"S Subramasnian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095138","display_name":"DEKK-TEC (United States)","ror":"https://ror.org/00hy18g46","country_code":"US","type":"company","lineage":["https://openalex.org/I4210095138"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S Subramasnian","raw_affiliation_strings":["DEKK-TEC Inc., New Orleans, LO 70119, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DEKK-TEC Inc., New Orleans, LO 70119, USA","institution_ids":["https://openalex.org/I4210095138"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106922817","display_name":"Andrew H. Rodgers","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A H Rodgers","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108489225","display_name":"Lee Roy Morgan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L R Morgan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079400759","display_name":"Kenneth F. Soike","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K Soike","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5029584058","display_name":"M Ratteree","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M Ratteree","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.17780614,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"1","issue":"1","first_page":"62","last_page":"5"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.43950000405311584,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.43950000405311584,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.1550000011920929,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10704","display_name":"Advancements in Transdermal Drug Delivery","score":0.10170000046491623,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/plasma-drug-concentration","display_name":"plasma drug concentration","score":0.531000018119812},{"id":"https://openalex.org/keywords/topical-drug-delivery","display_name":"topical drug delivery","score":0.5379999876022339},{"id":"https://openalex.org/keywords/dermal-application","display_name":"dermal application","score":0.6800000071525574},{"id":"https://openalex.org/keywords/cutaneous-metastasis","display_name":"cutaneous metastasis","score":0.8610000014305115},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.8960000276565552},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.921999990940094},{"id":"https://openalex.org/keywords/kaposi-sarcoma","display_name":"Kaposi's sarcoma","score":0.9390000104904175},{"id":"https://openalex.org/keywords/lymphoproliferative-disorders","display_name":"lymphoproliferative disorders","score":0.9369999766349792},{"id":"https://openalex.org/keywords/anticancer-agents","display_name":"anticancer agents","score":0.8299999833106995},{"id":"https://openalex.org/keywords/cross-species-comparison","display_name":"cross-species comparison","score":0.5419999957084656}],"concepts":[{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.9240972995758057},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6149033904075623},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5741252303123474},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5559866428375244},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.4761257767677307},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.47213107347488403},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4656791090965271},{"id":"https://openalex.org/C3020079912","wikidata":"https://www.wikidata.org/wiki/Q3918988","display_name":"Plasma concentration","level":2,"score":0.45051637291908264},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.44524991512298584},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4335966110229492},{"id":"https://openalex.org/C3017575891","wikidata":"https://www.wikidata.org/wiki/Q3918988","display_name":"Plasma levels","level":2,"score":0.4294366240501404},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.30008357763290405},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.15308961272239685}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D002522","descriptor_name":"Chlorocebus aethiops","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002851","descriptor_name":"Chromatography, High Pressure Liquid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006835","descriptor_name":"Hydrazones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006835","descriptor_name":"Hydrazones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006835","descriptor_name":"Hydrazones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D007271","descriptor_name":"Injections, Intradermal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010636","descriptor_name":"Phenols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010636","descriptor_name":"Phenols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010636","descriptor_name":"Phenols","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:9414389","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9414389","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of experimental therapeutics & oncology","raw_type":"Comparative Study"},{"id":"mag:2402377796","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9414389","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2394574730","https://openalex.org/W2398269894","https://openalex.org/W1993461412","https://openalex.org/W2009108794","https://openalex.org/W6958688692","https://openalex.org/W2006191814","https://openalex.org/W1973964449","https://openalex.org/W2952555395","https://openalex.org/W1965148821","https://openalex.org/W2035058238"],"abstract_inverted_index":{"4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone":[0],"(A-007)":[1],"is":[2,77,107,113,122],"being":[3],"evaluated":[4],"for":[5,41,68,129,144,156],"its":[6],"anticancer":[7],"activities":[8],"in":[9,27,30,54,57,109,116],"melanoma,":[10],"breast":[11,146],"cancer,":[12],"Kaposi's":[13],"sarcoma":[14],"and":[15,32,59,85],"lymphoproliferative":[16],"disorders.":[17],"A":[18],"single":[19,46],"oral":[20,47,96],"dose":[21,48],"of":[22,25,49,52,82,104,138,159],"1":[23],"g/kg":[24,51],"A-007":[26,53,112,139,160],"rats":[28],"resulted":[29,56],"prolonged":[31,58],"low":[33,60],"plasma":[34,61,117],"levels,":[35,62],"typically":[36,63],"less":[37,64],"than":[38,65],"150":[39],"ng/ml":[40,67],"several":[42,69],"days.":[43,70,131],"Similarly,":[44],"a":[45,119,153],"5":[50],"monkeys":[55],"22":[66],"Oral":[71],"bioavailability":[72,97],"data":[73,150],"suggests":[74],"that":[75],"this":[76],"not":[78,114],"an":[79,101],"efficient":[80],"mode":[81],"drug":[83,105],"administration":[84],"availability":[86],"diminishes":[87],"as":[88],"one":[89],"progresses":[90],"from":[91],"rodents":[92],"to":[93,125,140,161],"primates":[94],"(relative":[95],"2%);":[98],"thus":[99],"suggesting":[100],"alternative":[102],"form":[103],"delivery":[106],"required":[108],"higher":[110],"species.":[111],"detected":[115],"after":[118],"0.25%":[120],"gel":[121],"applied":[123],"topically":[124],"the":[126,135,157],"skin":[127],"daily":[128],"28":[130],"Early":[132],"clinical":[133],"support":[134,152],"topical":[136],"use":[137,158],"treat":[141,162],"cutaneous":[142,164],"metastasis":[143],"human":[145],"cancer.":[147],"The":[148],"present":[149],"further":[151],"dermal":[154],"approach":[155],"metastatic":[163],"cancers.":[165]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}